230 related articles for article (PubMed ID: 35356854)
1. N
Ren Z; Hu Y; Sun J; Kang Y; Li G; Zhao H
Bioengineered; 2022 Apr; 13(4):7963-7973. PubMed ID: 35356854
[TBL] [Abstract][Full Text] [Related]
2. N
Huang T; Cao L; Feng N; Xu B; Dong Y; Wang M
Bioengineered; 2021 Dec; 12(2):10935-10944. PubMed ID: 34866525
[TBL] [Abstract][Full Text] [Related]
3. AGAP2-AS1 promotes the assembly of m6A methyltransferases and activation of the IL6/STAT3 pathway by binding with WTAP in the carcinogenesis of gastric cancer.
Nie K; Zheng Z; Li J; Chang Y; Deng Z; Huang W; Li X
FASEB J; 2023 Dec; 37(12):e23302. PubMed ID: 37983949
[TBL] [Abstract][Full Text] [Related]
4. m
Ji F; Lu Y; Chen S; Lin X; Yu Y; Zhu Y; Luo X
Mol Ther Oncolytics; 2021 Sep; 22():574-581. PubMed ID: 34589576
[TBL] [Abstract][Full Text] [Related]
5. HIF-1α induced long noncoding RNA FOXD2-AS1 promotes the osteosarcoma through repressing p21.
Ren Z; Hu Y; Li G; Kang Y; Liu Y; Zhao H
Biomed Pharmacother; 2019 Sep; 117():109104. PubMed ID: 31228799
[TBL] [Abstract][Full Text] [Related]
6. Long noncoding RNA OIP5-AS1 accelerates CDK14 expression to promote osteosarcoma tumorigenesis via targeting miR-223.
Dai J; Xu L; Hu X; Han G; Jiang H; Sun H; Zhu G; Tang X
Biomed Pharmacother; 2018 Oct; 106():1441-1447. PubMed ID: 30119217
[TBL] [Abstract][Full Text] [Related]
7. WTAP-mediated m
Li ZX; Zheng ZQ; Yang PY; Lin L; Zhou GQ; Lv JW; Zhang LL; Chen F; Li YQ; Wu CF; Li F; Ma J; Liu N; Sun Y
Cell Death Differ; 2022 Jun; 29(6):1137-1151. PubMed ID: 34999731
[TBL] [Abstract][Full Text] [Related]
8. LncRNA FOXD2-AS1 knockdown inhibits the resistance of human osteosarcoma cells to cisplatin by inhibiting miR-143 expression.
Zhang QQ; Xu SL; Ding C; Ma CC; Yuan TS; Hua CC; Wang XH
Eur Rev Med Pharmacol Sci; 2021 Jan; 25(2):678-686. PubMed ID: 33577022
[TBL] [Abstract][Full Text] [Related]
9. WTAP promotes osteosarcoma tumorigenesis by repressing HMBOX1 expression in an m
Chen S; Li Y; Zhi S; Ding Z; Wang W; Peng Y; Huang Y; Zheng R; Yu H; Wang J; Hu M; Miao J; Li J
Cell Death Dis; 2020 Aug; 11(8):659. PubMed ID: 32814762
[TBL] [Abstract][Full Text] [Related]
10. LncRNA MEG3 negatively modified osteosarcoma development through regulation of miR-361-5p and FoxM1.
Shen B; Zhou N; Hu T; Zhao W; Wu D; Wang S
J Cell Physiol; 2019 Aug; 234(8):13464-13480. PubMed ID: 30624782
[TBL] [Abstract][Full Text] [Related]
11. Long noncoding RNA FOXD2-AS1 promotes glioma malignancy and tumorigenesis via targeting miR-185-5p/CCND2 axis.
Shen F; Chang H; Gao G; Zhang B; Li X; Jin B
J Cell Biochem; 2019 Jun; 120(6):9324-9336. PubMed ID: 30520141
[TBL] [Abstract][Full Text] [Related]
12. LncRNA DICER1-AS1 promotes the proliferation, invasion and autophagy of osteosarcoma cells via miR-30b/ATG5.
Gu Z; Hou Z; Zheng L; Wang X; Wu L; Zhang C
Biomed Pharmacother; 2018 Aug; 104():110-118. PubMed ID: 29772430
[TBL] [Abstract][Full Text] [Related]
13. Targeting the FOXM1-regulated long noncoding RNA TUG1 in osteosarcoma.
Li Y; Zhang T; Zhang Y; Zhao X; Wang W
Cancer Sci; 2018 Oct; 109(10):3093-3104. PubMed ID: 30099814
[TBL] [Abstract][Full Text] [Related]
14. The long non-coding RNA FOXD2-AS1 promotes bladder cancer progression and recurrence through a positive feedback loop with Akt and E2F1.
Su F; He W; Chen C; Liu M; Liu H; Xue F; Bi J; Xu D; Zhao Y; Huang J; Lin T; Jiang C
Cell Death Dis; 2018 Feb; 9(2):233. PubMed ID: 29445134
[TBL] [Abstract][Full Text] [Related]
15. Upregulation of the long noncoding RNA FOXD2-AS1 promotes carcinogenesis by epigenetically silencing EphB3 through EZH2 and LSD1, and predicts poor prognosis in gastric cancer.
Xu TP; Wang WY; Ma P; Shuai Y; Zhao K; Wang YF; Li W; Xia R; Chen WM; Zhang EB; Shu YQ
Oncogene; 2018 Sep; 37(36):5020-5036. PubMed ID: 29789713
[TBL] [Abstract][Full Text] [Related]
16. LncRNA MCF2L-AS1 aggravates proliferation, invasion and glycolysis of colorectal cancer cells via the crosstalk with miR-874-3p/FOXM1 signaling axis.
Zhang Z; Yang W; Li N; Chen X; Ma F; Yang J; Zhang Y; Chai X; Zhang B; Hou X; Luo S; Hua Y
Carcinogenesis; 2021 Feb; 42(2):263-271. PubMed ID: 32860508
[TBL] [Abstract][Full Text] [Related]
17. Overexpression of FOXD2-AS1 enhances proliferation and impairs differentiation of glioma stem cells by activating the NOTCH pathway via TAF-1.
Wang Y; Cheng Y; Yang Q; Kuang L; Liu G
J Cell Mol Med; 2022 May; 26(9):2620-2632. PubMed ID: 35419917
[TBL] [Abstract][Full Text] [Related]
18. Long noncoding RNA SLC2A1-AS1 regulates aerobic glycolysis and progression in hepatocellular carcinoma via inhibiting the STAT3/FOXM1/GLUT1 pathway.
Shang R; Wang M; Dai B; Du J; Wang J; Liu Z; Qu S; Yang X; Liu J; Xia C; Wang L; Wang D; Li Y
Mol Oncol; 2020 Jun; 14(6):1381-1396. PubMed ID: 32174012
[TBL] [Abstract][Full Text] [Related]
19. Long noncoding RNA FOXD2-AS1 promotes glioma cell cycle progression and proliferation through the FOXD2-AS1/miR-31/CDK1 pathway.
Wang J; Li B; Wang C; Luo Y; Zhao M; Chen P
J Cell Biochem; 2019 Dec; 120(12):19784-19795. PubMed ID: 31347720
[TBL] [Abstract][Full Text] [Related]
20. EGR1-induced upregulation of lncRNA FOXD2-AS1 promotes the progression of hepatocellular carcinoma via epigenetically silencing DKK1 and activating Wnt/β-catenin signaling pathway.
Lei T; Zhu X; Zhu K; Jia F; Li S
Cancer Biol Ther; 2019; 20(7):1007-1016. PubMed ID: 30929558
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
